Jacobs Levy Equity Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-460,842
| Closed | -$705K | – | 1024 |
|
|
2025
Q1 | $705K | Sell |
460,842
-115,200
| -20% | -$176K | ﹤0.01% | 873 |
|
|
2024
Q4 | $1.43M | Sell |
576,042
-339,467
| -37% | -$842K | 0.01% | 657 |
|
|
2024
Q3 | $1.05M | Buy |
+915,509
| New | +$1.05M | ﹤0.01% | 715 |
|
|
2024
Q1 | – | Sell |
-748,775
| Closed | -$786K | – | 932 |
|
|
2023
Q4 | $786K | Buy |
748,775
+573,294
| +327% | +$602K | ﹤0.01% | 764 |
|
|
2023
Q3 | $1.2M | Buy |
175,481
+124,132
| +242% | +$850K | 0.01% | 644 |
|
|
2023
Q2 | $532K | Sell |
51,349
-8,111
| -14% | -$84.1K | ﹤0.01% | 813 |
|
|
2023
Q1 | $481K | Buy |
+59,460
| New | +$481K | ﹤0.01% | 809 |
|
|
2020
Q1 | – | Sell |
-111,166
| Closed | -$210K | – | 994 |
|
|
2019
Q4 | $210K | Buy |
+111,166
| New | +$210K | ﹤0.01% | 931 |
|